Randomized Phase 2 Trial Of AG013736 [axitinib] Or Bevacizumab In Combination With Paclitaxel And Carboplatin As First Line Treatment For Patients With Advanced Non Small Cell Lung Cancer
Latest Information Update: 17 Dec 2021
Price :
$35 *
At a glance
- Drugs Axitinib (Primary) ; Bevacizumab; Carboplatin; Paclitaxel
- Indications Non-small cell lung cancer
- Focus Biomarker; Therapeutic Use
- 25 Oct 2012 Status changed from active, no longer recruiting to completed.
- 02 Oct 2012 Results presented at the 37th Congress of the European Society for Medical Oncology.
- 29 Sep 2012 Primary endpoint 'Progression-free-survival-duration' has not been met.